Avanir Pharmaceuticals, Inc. Reaches Agreement in Principle with U.S. Department of Justice Regarding NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) 20mg/10mg capsulesOdessa American3 days ago
Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in EuropeAssociated Press2 days ago
- Market Watch5 days ago
Otsuka America Pharmaceutical, Inc. 2440 Research Blvd, Rockville, MD 20850, United States Telephone 301-424-9055 Email Contact@otsuka-us.com Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical, Inc. researches, develops, manufactures, and markets pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday ...
OTSUKA AMERICA PHARMACEUTICAL, INC. Patient Assistance Program. Patient assistance programs (PAPs) are programs created by drug companies, such as OTSUKA AMERICA PHARMACEUTICAL, INC., to offer free or low cost drugs to individuals who are unable to pay for their medication.
Otsuka America Pharmaceutical, Inc. (OAPI) is an innovative, fast-growing healthcare company that commercializes Otsuka-discovered and in-licensed products in the U.S., with a strong focus on neuroscience, oncology, cardio-renal, and medical devices.
Otsuka Pharmaceutical Factory was first founded as Otsuka Seiyaku Kogyobu (Otsuka Pharmaceutical) in 1921 and is the original company from which the Otsuka group has grown. We develop intravenous solutions, along with medical foods such as oral rehydration solutions and many other innovative products to meet a wide range of needs.
In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion. In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus ...